0%

est. 2Y upside i

HealthcareSeries A

Enabling next generation medicines. A comprehensive platform and…

Rank

#2126

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Equity analysis is severely limited due to missing current valuation and revenue growth data.

Last updated: July 19, 2026

Bull (20%)0%

Valuation data missing; cannot compute upside. If valuation were $200M, 2x exit would require $400M market cap.

Base (55%)0%

Valuation data missing; cannot compute upside. Base case assumes moderate growth and multiple compression.

Bear (25%)-100%

If exit value below $59.6M total funding, common stock is worthless due to 1x preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

1656%

Total funding of $59.6M preferred stack would overhang common stock significantly if valuation is below ~$200M.

Dilution Risk

high

Likely to raise additional capital within 24 months given high capital intensity and limited runway from 2022 raise.

Secondary Liquidity

none

No secondary market activity reported; no current liquidity for employees.

Questions to Ask at the Interview

Strategic questions based on 64x Bio's data — designed to show you've done your homework.

  • 1

    “What is the current valuation and what mark was used for the last 409A?”

  • 2

    “How has revenue grown in the past 12 months, and what is the implied forward revenue multiple?”

  • 3

    “What is the expected timeline to liquidity (IPO or M&A) and any secondary market activity?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.